cancer radiotherapy treatment News
-
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA) have granted Orphan Drug Designation (ODD) to the company’s lead compound, TP508 (rusalatide acetate) for the treatment of acute radiation syndrome (ARS). With exposure to high levels of nuclear radiation, individuals ...
-
CSIRO at Australia’s biggest ICT trade show – CeBIT
CeBIT, the nation’s leading trade show for ICT industries and research organisations, is on in Sydney from 24-26 May. The CSIRO stand, staffed by experts in science, engineering and commercialisation, will feature displays of the following technology: augmented reality visualisation to enable remote delivery of complicated expert services in healthcare, education and controlling ...
-
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi`s First Dedicated Compact Proton Therapy System
Hitachi, Ltd. (TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s ...
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis ...
-
C4 Imaging Announces FDA 510(k) Clearance of its Non-metallic, Multimodality C4 Fiducial Marker
C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its third major product, the Multimodality C4 Fiducial Marker. This novel positive-signal MRI marker will be implanted into patients in situations where the location of specific anatomy, normal or diseased, needs to be marked for a future medical procedure. The device can be visualized using MRI, CT or x-ray, and ...
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you